Angiotech Looks To Genzyme For Cancer Combo Product Collaboration
This article was originally published in The Gray Sheet
Executive Summary
Angiotech is entering into a long-term partnership with biotechnology firm Genzyme to develop new oncology combination products
You may also be interested in...
With AMI Buy, Angiotech Looks To Become Less Reliant On Partnerships
Angiotech Pharmaceuticals' $785 mil. acquisition of American Medical Instruments Holdings will allow the firm to diversify its revenue stream and retain more control over its combination product business
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.